You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
步長製藥(603858.SH):控股子公司與GOODFELLOW簽署《獨家供應協議》

格隆匯8月7日丨步長製藥(603858.SH)公佈,在當前中國醫藥企業積極“走出去”的大背景下,爲實現山東步長製藥股份有限公司產品國際化戰略,爲公司帶來更好的經濟效益,同時提升公司品牌的影響力,公司控股子公司四川瀘州步長生物製藥有限公司(簡稱“瀘州步長”)擬與菲律賓公司GOODFELLOWPHARMACORPORATION(簡稱“GOODFELLOW”)簽署《獨家供應協議》,瀘州步長擬授權GOODFELLOW作爲菲律賓區域(簡稱“目標區域”)內獨家代理商,在目標區域內完成注射用Efparepoetinalfa(簡稱“目標產品”)的註冊、相關臨牀試驗、推廣、分銷及銷售事宜。注射用Efparepoetinalfa(注射用依派促紅素α),適用於治療正在接受促紅細胞生成素治療的成人透析患者因慢性腎臟病(CKD)引起的貧血,爲治療用生物製品I類新藥,目前已提交上市申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account